THERAPEUTIC COMBINATIONS COMPRISING POLY(ADP-RIBOSE) POLYMERASES INHIBITOR

The invention generally relates to use of 8-fluoro-2{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H -azepino[5,4,3-cd]indol-6-one representedby Formula (1) as a chemosensitizer that enhances the efficacy of cytotoxic drugsor radiotherapy. This invention provides pharmaceutical combinations of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CURTIN, NICOLA JANE, JONES, CHRISTOPHER, DEWJI, MOHAMED RAZA, CALVERT, ALAN HILARY, STEINFELDT, HEIDIE MARIE, PLUMMER, ELIZABETH RUTH, BORITZKI, THEODORE JAMES, KAUFMAN, RHONDA, HOSTOMSKY, ZDENEK, REICHN, STEVEN DAVID, KLAMERUS, KAREN J, THOMAS, HUM DAVID, STRATFORD, IAN J, WILLIAMS, KAYE JANINE
Format:	Patent
Sprache:	eng ; spa
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention generally relates to use of 8-fluoro-2{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H -azepino[5,4,3-cd]indol-6-one representedby Formula (1) as a chemosensitizer that enhances the efficacy of cytotoxic drugsor radiotherapy. This invention provides pharmaceutical combinations of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6 H-azepino[5,4,3-cd]indol-6-one, ora pharmaceutically acceptable salt thereof and at least one additional therapeutic agent,kits containing such combinations and methods of using such combinations totreat subjects suffering from diseases such as cancer. Esta invencion se refiere en lineas generales al uso de 8-fluoro-2-(4-[(metilamino)metil]fenil(-1,3,4,5-tetrahidro-6H- azepino[5,4,3-cd]indol-6-ona representado por la formula 1 como quimiosensibilizador que potencia la eficacia de farmacos citotoxicos o radioterapia. (Ver Formula 1), esta invencion proporciona combinaciones farmaceuticas de 8-fluoro-2-(4-[( metilamino)metil]fenil(-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd] indol-6-ona, o una sal farmaceuticamente aceptable de la misma y al menos un agente terapeutico adicional, kits que contiene dichas combinaciones y procedimientos para usar dichas combinaciones para tratar sujetos que padecen de enfermedades tales como cancer.